Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €66.96 EUR
Change Today -0.008 / -0.01%
Volume 120.0
As of 1:34 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

st jude medical inc (JUD) Snapshot

Open
€66.99
Previous Close
€66.97
Day High
€67.67
Day Low
€66.81
52 Week High
07/20/15 - €71.16
52 Week Low
10/15/14 - €44.00
Market Cap
18.8B
Average Volume 10 Days
147.2
EPS TTM
--
Shares Outstanding
281.2M
EX-Date
06/26/15
P/E TM
--
Dividend
€1.14
Dividend Yield
1.43%
Current Stock Chart for ST JUDE MEDICAL INC (JUD)

st jude medical inc (JUD) Related Businessweek News

View More BusinessWeek News

st jude medical inc (JUD) Details

St. Jude Medical, Inc., together with its subsidiaries, develops, manufactures and distributes cardiovascular medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. The company offers tachycardia implantable cardioverter defibrillator systems and cardiac resynchronization therapy defibrillator devices to treat patients suffering from lethal heart conditions, such as sudden cardiac arrest or heart failure. It also provides pacemakers, which deliver low-voltage electrical impulses to stimulate a heartbeat for patients whose hearts beat too slowly; and atrial fibrillation products comprising electrophysiology, introducers and catheters, advanced cardiac mapping, navigation and recording systems, and ablation systems. In addition, the company offers vascular closure devices, compression assist devices, pressure measurement guidewires, diagnostic coronary imaging technology, percutaneous catheter introducers, diagnostic guidewires, renal denervation technology and vascular plugs, optical coherence tomography imaging products, and other vascular accessories, as well as CardioMEMS, a heart failure monitoring device. Further, it provides structural heart products, including transcatheter aortic heart valves, various surgical heart valve repair and replacement products, and transcatheter structural heart defect devices; and neuromodulation products, such as spinal cord stimulation and radiofrequency ablation to treat chronic pain, as well as deep brain stimulation to treat movement disorders. The company sells its products through direct sales force and independent distributors. St. Jude Medical, Inc. was founded in 1976 and is headquartered in St. Paul, Minnesota.

16,000 Employees
Last Reported Date: 02/26/15
Founded in 1976

st jude medical inc (JUD) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.1M
Chief Financial Officer and Vice President of...
Total Annual Compensation: $468.8K
Chief Operating Officer
Total Annual Compensation: $788.3K
President of International Division
Total Annual Compensation: $752.4K
Group President
Total Annual Compensation: $708.5K
Compensation as of Fiscal Year 2014.

st jude medical inc (JUD) Key Developments

St. Jude Medical Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended July 4, 2015; Provides Earnings Guidance for the Third Quarter and Full Year of 2015

St. Jude Medical Inc. reported unaudited consolidated earnings results for the second quarter and six months ended July 4, 2015. For the quarter, the company reported net sales of $1,410 million compared to $1,448 million a year ago. Operating profit was $314 million compared to $289 million a year ago. Earnings before non-controlling interest and income taxes were $294 million compared to $268 million a year ago. Net earnings attributable to the company were $290 million or $1.02 per diluted share compared to $270 million or $0.93 per diluted share a year ago. Adjusted net earnings attributable to the company were $293 million or $1.03 per diluted share compared to $308 million or $1.07 per diluted share a year ago. Adjusted earnings before non-controlling interest and income taxes were $289 million compared to $300 million a year ago. For the six months period, the company reported net sales of $2,755 million compared to $2,811 million a year ago. Operating profit was $639 million compared to $601 million a year ago. Earnings before non-controlling interest and income taxes were $602 million compared to $560 million a year ago. Net earnings attributable to the company were $552 million or $1.80 per diluted share compared to $519 million or $1.80 per diluted share a year ago. Adjusted net earnings attributable to the company were $559 million or $1.95 per diluted share compared to $599 million or $2.07 per diluted share a year ago. Adjusted earnings before non-controlling interest and income taxes were $549 million compared to $581 million a year ago. For the third quarter, the company expects revenue to grow in the range of 5% to 7% on a constant currency basis compared to the third quarter of 2014 with currency negatively impacting third quarter revenue by approximately $105 million to $115 million. The company expects its consolidated adjusted net earnings for the third quarter of 2015 to be in the range of $0.96 to $0.98 per share. Estimated amortization of intangible assets was $0.06 per share. For the full-year 2015, the company expects total revenue to grow in the range of 4% to 6% on a constant currency basis with currency negatively impacting full-year 2015 revenue by approximately $385 million to $410 million. The company expects its consolidated adjusted net earnings for the full-year 2015 consolidated adjusted net earnings to be in the range of $3.96 to $4.00. Estimated amortization of intangible assets was $0.23 per share. The company now expects the effective tax rate to be approximately 17.0%.

St. Jude Medical Announces FDA Approval for MR-Conditional 5-Column Paddle Lead for the Management of Chronic Pain

St. Jude Medical Inc. announced U.S. Food and Drug Administration approval of MR-conditional labeling for the company’s Penta™ 5-column paddle lead for spinal cord stimulation (SCS) therapy to manage chronic pain. The Penta lead, which will be available for use with the company’s Protégé MRI™ system in the U.S., is the only five-column paddle lead on the market that will allow patients to safely undergo head and extremity MRI scans. For some chronic pain patients, the potential need for future MRI scans has historically acted as a barrier to SCS therapy. Throughout 2015, St. Jude Medical has introduced a series of MR-conditional implantable pulse generators (IPG’s) and leads designed to improve patient access to the latest chronic pain therapy options while preserving the ability to undergo head and extremity MRI scans. With the newly approved updated labeling, the Penta paddle lead will be available for use with the Protégé MRI system, which is the smallest upgradeable MR-conditional SCS IPG available in the U.S. In an SCS system, an IPG generates electrical energy, which is delivered via leads to nerve fibers along the spine to interrupt pain signals as they travel to the brain, reducing the sensation of pain.

St. Jude Medical Inc. Announces FDA Approval of the St. Jude Medical™ Invisible Trial System

St. Jude Medical Inc. announced FDA approval of the St. Jude Medical™ Invisible Trial System. The system, which received CE Mark in June 2015, is fully wireless and leverages Apple™ technology for both the patient and physician controllers. The system is designed to provide patients a more improved and discreet spinal cord stimulation (SCS) trial experience. For many patients, SCS therapy can be an effective option for managing chronic pain. The therapy relies on a small implanted device and thin wires (known as leads) to deliver low levels of electrical energy to mask or interrupt pain signals as they travel along nerve fibers to the brain, which reduces the sensation of pain. Prior to receiving a permanently implanted SCS device, patients undergo a minimally invasive “trial” period to evaluate the therapy. Yet for some patients, complex controllers and bulky programming cables can disrupt the trial experience and act as barrier to SCS therapy. With the Invisible Trial System, St. Jude Medical has removed these barriers, allowing patients to more effectively evaluate their SCS therapy. The system relies on Bluetooth® wireless technology to provide patients a safe, secure and entirely wireless SCS trial experience. Rather than a complex controller, the St. Jude Medical Invisible Trial System provides patients with a more intuitive iPod touch™ digital device as a controller, while physicians will utilize an iPad mini™ digital device to program and evaluate their patient’s therapy. One of the key system features of the St. Jude Medical Invisible Trial System is the use of a small external pulse generator (EPG) as the system’s power source. Because the EPG uses Bluetooth wireless technology to communicate between the patient’s iPod touch controller and the stimulation system, the overall device profile has been reduced so the system can be worn discreetly under a patient’s clothing. The effect is that the system feels essentially “invisible” to the wearer, providing a more comfortable trial experience that allows patients to focus entirely on their system’s therapeutic impact during their trial.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JUD:GR €66.96 EUR -0.008

JUD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $17.11 USD -0.23
CR Bard Inc $196.19 USD -0.46
Olympus Corp ¥4,815 JPY +75.00
Smith & Nephew PLC 1,188 GBp -1.00
Zimmer Biomet Holdings Inc $104.33 USD +0.26
View Industry Companies
 

Industry Analysis

JUD

Industry Average

Valuation JUD Industry Range
Price/Earnings 20.6x
Price/Sales 3.8x
Price/Book 5.5x
Price/Cash Flow 18.4x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit www.sjm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.